Rapid communicationPrion-like acceleration of a synucleinopathy in a transgenic mouse model
Introduction
Pathological accumulation of misfolded neuronal proteins, leading to synaptic dysfunction and cell death, is assumed to play a central role in the pathogenesis of many neurodegenerative disorders. Although synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB), are not infectious pathologies, recent studies suggested the existence of common mechanisms underlying the propagation of α-synuclein (α-syn) and prion alterations (Angot et al., 2010). Here, we investigated the potential in vivo transmission of a synucleinopathy, using a transgenic mouse model (TgM83) expressing the human A53T mutated α-synuclein (Giasson et al., 2002).
Section snippets
Animal bioassays
Homozygous TgM83 mice (7–9 weeks old) were inoculated intracerebrally with 20 μL of 1% (wt/vol in glucose 5%) homogenates obtained from half of the brain of old (12–18 months) TgM83 mice euthanized following the development of clinical signs due to the α-syn pathology. Controls included: (1) uninoculated TgM83 mice, (2) TgM83 mice inoculated with a brain homogenate from a 2-month-old healthy TgM83 mouse, and (3) C57Bl/6S mice, presenting a deletion of the α-syn locus (Harlan, Gannat, France) (
Results
A transgenic mouse model of synucleinopathy was used (TgM83) (Giasson et al., 2002), in which mice develop a severe motor impairment associated with detection of insoluble pSer129 α-syn only at a late stage of the disease (Mougenot et al., 2011, Waxman and Giasson, 2008).
No statistically significant difference was found (p = 0.273) between the survival times of TgM83 mice uninoculated (median 435 days old) or inoculated with a brain homogenate from a 2-month-old healthy TgM83 mouse (median 359
Discussion
The common feature of synucleinopathies is the accumulation of intracellular aggregates of α-syn that spread throughout the brain. Possible similarities in propagation of the α-syn pathology with that of prions have been highlighted in recent studies (Angot et al., 2010). We therefore adopted the procedures routinely performed to transmit prion diseases in mice, using i.c. inoculation of brain homogenates of affected animals, in a transgenic mouse model of human synucleinopathy (TgM83) (Giasson
Disclosure statement
The authors declare no conflicts of interest.
The animals were cared for and housed in approved experimental facilities (n°A69387081), in accordance with the EC Directive 86/609/EEC and with the Regional Committee for Ethical Experimentation on Animals (protocol n°98).
Acknowledgements
We are grateful to D. Bétemps, J.-M. Bridon, M. Leboidre, and to the staff of Plate-forme d'expérimentation animale Anses-Lyon for their contribution to the study. A.-L.M. was supported by a training grant (CIFRE 2006/1050) from the Association Nationale pour la Recherche et la Technologie.
References (7)
- et al.
Are synucleinopathies prion-like disorders?
Lancet Neurol
(2010) - et al.
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein
Neuron
(2002) - et al.
Transmission and spreading of tauopathy in transgenic mouse brain
Nat. Cell Biol.
(2009)
Cited by (304)
The influence of zwitterionic and anionic phospholipids on protein aggregation
2024, Biophysical ChemistryPreclinical Evaluation of Novel PET Probes for Dementia
2023, Seminars in Nuclear Medicineα-Synuclein Conformational Strains as Drivers of Phenotypic Heterogeneity in Neurodegenerative Diseases
2023, Journal of Molecular BiologySpreading of alpha-synuclein between different cell types
2023, Behavioural Brain Research